This recombinant monoclonal antibody is developed as a research-grade biosimilar to CM369, targeting CCR8 (C-C motif chemokine receptor 8), a G protein-coupled receptor predominantly expressed on regulatory T cells (Tregs) and certain T helper cell subsets. CCR8 mediates chemotaxis in response to its ligands CCL1 and CCL18, playing a crucial role in immune regulation and T cell trafficking to tissues. This receptor has emerged as a significant marker of tumor-infiltrating Tregs across multiple cancer types, where it contributes to the immunosuppressive tumor microenvironment by facilitating Treg accumulation and function.
CM369 is a reference antibody that has been utilized in preclinical research to investigate CCR8's role in cancer immunology and autoimmune disorders. This biosimilar provides researchers with a valuable tool for studying CCR8-mediated immune regulation, exploring therapeutic strategies targeting tumor-associated Tregs, and investigating the receptor's involvement in inflammatory diseases. The antibody supports investigations into immunotherapy approaches and mechanisms of immune evasion in oncology research.
Email: support@cusabio.com
Distributors Worldwide